+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032- Product Image
Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032- Product Image
New

Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904662
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-obesity prescription drugs market is undergoing a period of significant transformation, driven by advancements in clinical science, digital integration, and new regulatory norms. Senior leaders seeking to deliver competitive solutions must anticipate shifts in treatment modalities, patient access, and the operational landscape.

Market Snapshot: Anti-Obesity Prescription Drugs Market

The Anti-Obesity Prescription Drugs Market recorded steady growth, rising from USD 7.25 billion in 2025 to USD 7.84 billion in 2026, and is projected to reach USD 12.77 billion by 2032 at a CAGR of 8.40%. This expansion is attributed to increasing demand for next-generation clinical options, broader adoption across diverse care settings, and the strengthening of global supply and distribution networks. This momentum is reinforced by the wider acceptance of obesity as a chronic condition, underscoring the importance of effective, accessible pharmacological therapies for long-term management. The sector’s evolution necessitates adaptive strategies responsive to innovation, regulatory shifts, and global health priorities.

Scope & Segmentation

  • Drug Classes: This market incorporates Amylin Analogs (e.g., Pramlintide), GLP-1 Agonists (such as Dulaglutide, Exenatide, Liraglutide, Semaglutide), Lipase Inhibitors (Orlistat), and Serotonin Receptor Modulators (Locaserin), each of which is defined by distinct clinical indications and mechanisms of action relevant for targeted obesity interventions.
  • Administration Routes: Includes a comprehensive set of options, such as injectable formats (auto-injectors, prefilled pens, vials, syringes) and oral treatments (capsules, tablets), enabling alignment with patient needs and healthcare provider workflows.
  • Distribution Channels: Encompasses a spectrum from traditional channels like clinics, pharmacies, and hospitals to digital options, including online pharmacies, telehealth, and direct-to-patient delivery, driven by ongoing digitization and greater focus on patient convenience.
  • End User Settings: Addresses a variety of use cases in ambulatory care centers, home care environments, hospitals, and specialty clinics dedicated to endocrinology, general medicine, or comprehensive weight management.
  • Regions: Coverage spans Americas, Europe, Middle East & Africa, and Asia-Pacific, capturing the impact of differing regulatory environments, adoption curves, and healthcare infrastructure maturity across geographies.
  • Technologies: Examines the deployment of drug-device platforms, digital adherence solutions, and supply chain innovations that enhance patient engagement, therapy effectiveness, and operational efficiency.

Key Takeaways

  • Scientific advancements are enabling the development of more targeted pharmacological options, allowing providers to tailor obesity treatments and optimize clinical pathways in line with individualized patient profiles.
  • Modern delivery systems, including novel devices, are improving the ease of administration, supporting therapy adherence, streamlining clinical operations, and fostering partnerships between drug manufacturers and device companies.
  • Digital health integration allows for real-time care monitoring, expanding access for patients in remote or multidisciplinary settings and supporting the trend toward collaborative and connected obesity care models.
  • Detailed segmentation by drug class, administration method, distribution model, and care setting is increasingly important for accurate clinical positioning and market capture, ensuring that brands align with operational requirements of healthcare providers.
  • Regional differences in rules, reimbursement, and patient engagement require flexible, localized strategies to ensure compliance and enhance the likelihood of successful product introduction and sustainability.
  • Organizations are enhancing innovation through collaboration, the application of real-world evidence, and careful management of supply chains to mitigate risks and synchronize advancements in pharmaceutical and device development.

Tariff Impact Across the Anti-Obesity Prescription Drugs Value Chain

Recent changes to US tariffs have introduced new variables into the anti-obesity drug supply chain, specifically around production costs and sourcing dynamics. In response, manufacturers are evaluating dual sourcing, exploring onshore production, and updating procurement models to protect margins and maintain supply resilience. Contractual arrangements and procurement processes are being refined to reduce risks around key raw materials and device components, with heightened focus on maintaining the integrity of clinical trials and ongoing supply. Effective scenario planning and dynamic procurement are becoming essential tools for all market participants navigating uncertainties in trade policy.

Methodology & Data Sources

The research is based on primary interviews with clinicians, supply chain specialists, regulatory consultants, and senior commercial leaders, complemented by secondary evidence from clinical trials, company filings, device registries, and regulatory reports. Triangulating these sources provides a robust, accurate, and relevant analysis.

Why This Report Matters

  • Equips executive teams with actionable insights for aligning clinical innovation, commercial strategy, and operational execution in a dynamic market.
  • Supports data-driven decisions relating to device integration and resilient supply chain development.
  • Facilitates creation of tailored regional plans, considering differences in payer practices, regulation, and operational standards in global healthcare environments.

Conclusion

Ongoing advances in anti-obesity therapy and delivery, set against diverse regional landscapes, reinforce the need for integrated strategy and operational coordination to achieve sustainable market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anti-obesity Prescription Drugs Market, by Drug Class
8.1. Amylin Analogs
8.1.1. Pramlintide
8.2. GLP-1 Agonists
8.2.1. Dulaglutide
8.2.2. Exenatide
8.2.3. Liraglutide
8.2.4. Semaglutide
8.3. Lipase Inhibitors
8.3.1. Orlistat
8.4. Serotonin Receptor Modulators
8.4.1. Locaserin
9. Anti-obesity Prescription Drugs Market, by Administration Route
9.1. Injectables
9.1.1. Auto-Injectors
9.1.2. Prefilled Pens
9.1.3. Vials And Syringes
9.2. Orals
9.2.1. Capsules
9.2.2. Tablets
10. Anti-obesity Prescription Drugs Market, by End User
10.1. Ambulatory Care Centers
10.2. Home Care Settings
10.3. Hospitals
10.4. Specialty Clinics
10.4.1. Endocrinology Clinics
10.4.2. General Practice Clinics
10.4.3. Weight Loss Clinics
11. Anti-obesity Prescription Drugs Market, by Distribution Channel
11.1. Offline
11.2. Online
12. Anti-obesity Prescription Drugs Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Anti-obesity Prescription Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Anti-obesity Prescription Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Anti-obesity Prescription Drugs Market
16. China Anti-obesity Prescription Drugs Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Alizyme Limited
17.6. Amgen Inc.
17.7. AstraZeneca PLC
17.8. BioCon Limited
17.9. Boehringer Ingelheim International GmbH
17.10. CHEPLAPHARM Arzneimittel GmbH
17.11. Currax Pharmaceuticals LLC
17.12. Eli Lilly and Company
17.13. F. Hoffmann-La Roche Ltd.
17.14. Gelesis Holdings, Inc.
17.15. GlaxoSmithKline PLC
17.16. Hanmi Pharm.Co., Ltd.
17.17. HK inno.N Corporation
17.18. Innovent Biologics, Inc.
17.19. Merck & Co., Inc.
17.20. Novo Nordisk A/S
17.21. Orexigen Therapeutics, Inc.
17.22. Pfizer Inc.
17.23. Reddy’s Laboratories Limited
17.24. Rhythm Pharmaceuticals, Inc.
17.25. Takeda Pharmaceutical Company Limited
17.26. Teva Pharmaceuticals Company Limited
17.27. Verdiva Pharma Inc.
17.28. Vivus LLC
17.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 151. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 173. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 174. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 175. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 178. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 196. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 198. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 199. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 200. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 201. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 203. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 206. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 207. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 208. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 210. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 211. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 212. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 213. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 215. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 231. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 232. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 233. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 234. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 235. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 236. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 237. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 239. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 243. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 244. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 246. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 247. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 248. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 249. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 251. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 254. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 255. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 256. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 258. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 259. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 260. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 261. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 263. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 264. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 277. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 278. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
TABLE 280. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
TABLE 281. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
TABLE 282. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
TABLE 283. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 284. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
TABLE 285. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
TABLE 286. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
TABLE 288. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anti-obesity Prescription Drugs market report include:
  • Alizyme Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • BioCon Limited
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Holdings, Inc.
  • GlaxoSmithKline PLC
  • Hanmi Pharm.Co., Ltd.
  • HK inno.N Corporation
  • Innovent Biologics, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Reddy’s Laboratories Limited
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Company Limited
  • Verdiva Pharma Inc.
  • Vivus LLC
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 12.77 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Anti-Obesity Therapeutics Market - Global Forecast 2026-2032 - Product Image

Anti-Obesity Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Obesity Treatment Market - Global Forecast 2026-2032 - Product Image

Obesity Treatment Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Deoxycholic Acid Obesity Drugs Market Report 2025 - Product Image

Deoxycholic Acid Obesity Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032 - Product Image

Global Digital Health For Obesity Market Size, Share & Industry Analysis Report By Component (Services, Software, and Hardware), By End-use (Patients, Providers, Payers, and Other End-use.), By Regional Outlook and Forecast, 2025 - 2032

  • Report
  • 358 Pages
  • Global
From
Obesity Market Report and Forecast 2025-2034 - Product Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From

About the Anti Obesity Prescription Drugs Market

The Anti-Obesity Prescription Drugs market is a segment of the healthcare industry focused on the development, production, and marketing of medication designed to combat obesity. These medications are intended for individuals who are unable to achieve weight loss through diet and exercise alone. Anti-obesity drugs work through various mechanisms, including appetite suppression, increased energy expenditure, and decreased nutrient absorption. The market encompasses a variety of drug classes, such as lipase inhibitors, serotonin receptor agonists, and others, each targeting different pathways related to weight regulation. The use of anti-obesity prescription drugs is typically recommended for those with a body mass index (BMI) above a certain threshold or for overweight individuals with weight-related health conditions such as diabetes or high blood pressure. The development of these pharmacological agents is guided by stringent regulatory standards to ensure their efficacy and safety. Market players invest in research and development to introduce more effective treatments with fewer side effects, as obesity remains a leading health concern. Several companies are key contributors to the Anti-Obesity Prescription Drugs market. Some of the well-known players include Novo Nordisk, GlaxoSmithKline, Roche, and Vivus, Inc. These companies are involved in manufacturing FDA-approved prescription drugs and are engaged in ongoing research to improve existing treatments and bring new solutions to the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.